Identification of inositol monophosphatase as a broad-spectrum antiviral target of ivermectin

J Med Virol. 2024 Mar;96(3):e29552. doi: 10.1002/jmv.29552.

Abstract

Ivermectin has broad-spectrum antiviral activities. Despite the failure in clinical application of COVID-19, it can serve as a lead compound for the development of more effective broad-spectrum antivirals, for which a better understanding of its antiviral mechanisms is essential. We thus searched for potential novel targets of ivermectin in host cells by label-free thermal proteomic profiling using Huh-7 cells. Inositol monophosphatase (IMPase) was found among the proteins with shifted thermal stability by ivermectin. Ivermectin could inhibit IMPase activity and reduce cellular myo-inositol and phosphatidylinositol-4-phosphate levels. On the other hand, inositol could impair the antiviral activity of ivermectin and lithium, an IMPase inhibitor with known antiviral activity. As phosphatidylinositol phosphate is crucial for the replication of many RNA viruses, inhibition of cellular myo-inositol biosynthesis may be an important antiviral mechanism of ivermectin. Hence, inhibition of IMPase could serve as a potential target for broad-spectrum antiviral development.

Keywords: antiviral; inositol monophosphatase; ivermectin; lithium chloride; phosphatidylinositol‐4‐phosphate; thermal proteomic profiling.

MeSH terms

  • 5'-Nucleotidase*
  • Antiviral Agents / pharmacology
  • Humans
  • Inositol / pharmacology
  • Ivermectin* / pharmacology
  • Phosphoric Monoester Hydrolases*
  • Proteomics

Substances

  • myo-inositol-1 (or 4)-monophosphatase
  • Ivermectin
  • 5'-Nucleotidase
  • Inositol
  • Antiviral Agents
  • Phosphoric Monoester Hydrolases